Resources from the same session
Should we exclude immunotherapy in case of advanced NSCLC with oncogenic addiction?
Presenter: JORDI REMON MASIP
Session: ETOP-IBCSG: Questions still unanswered in advanced NSCLC
Resources:
Slides
Webcast
When can or should anti-PD(L)-1s be stopped in advanced NSCLC?
Presenter: Silvia Novello
Session: ETOP-IBCSG: Questions still unanswered in advanced NSCLC
Resources:
Slides
Webcast
New developments in the treatment of immunotherapy-induced toxicities
Presenter: Michel Obeid
Session: ETOP-IBCSG: Questions still unanswered in advanced NSCLC
Resources:
Slides
Webcast
Q&A and discussion
Session: ETOP-IBCSG: Questions still unanswered in advanced NSCLC
Resources:
Webcast